Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells

International Journal of Cancer

Volumn 130, Issue 11, 2012, Pages 2495-2504

  Yu, Vanessa M ^a   Marion, Christine M ^a   Austria, Theresa M ^a   Yeh, Jennifer ^a   Schönthal, Axel H ^a   Dubeau, Louis ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

aneuploidy; BRCA1; cell cycle checkpoints; cellular aging; ovarian cancer

Indexed keywords

BRCA1 PROTEIN;

ANAPHASE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYSTADENOMA; CYTOKINESIS; DNA CONTENT; IN VITRO STUDY; MITOSIS INHIBITION; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION;

BRCA1 PROTEIN; CELL DIVISION; CYSTADENOMA; CYTOKINESIS; FEMALE; HUMANS; MITOSIS; OVARIAN NEOPLASMS; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 84859163287     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26309     Document Type: Article

References (45)

1. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266: 120-2.
2. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
3. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R,. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996; 14: 430-40.
4. Bell DW, Varley JM, Szydlo TE,. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-31.
5. Cortez D, Wang Y, Qin J, Elledge SJ,. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286: 1162-6.
6. Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK,. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem 2001; 276: 17276-80.
7. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW, Ouchi T,. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004; 179: 19643-8.
8. Sankaran S, Crone DE, Palazzo RE, Parvin JD,. BRCA1 regulates gamma-tubulin binding to centrosomes. Cancer Biol Ther 2007; 6: 1853-7.
9. Starita LM, Machida Y, Sankaran S, Elias JE, Griffin K, Schlegel BP, Gygi SP, Parvin JD,. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol 2004; 24: 8457-66.
10. Babu JR, Jeganathan KB, Baker DJ, Wu X, Kang-Decker N, van Deursen JM,. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J Cell Biol 2003; 160: 341-53.
11. Dai W, Want Q, Liu T, Swamy M, Fang Y, Xie S, Mahmood R, Yang YM, Xu M, Rao CV,. Slippage of mitotic arrest and enahanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res 2004; 62: 440-5.
12. Michael LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, Dobles M, Sorger PK, Murty VV, Benezra R,. Mad2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001; 409: 355-9.
13. Luo MP, Gomperts B, Imren S, DeClerck YA, Ito M, Velicescu M, Felix JC, Dubeau L,. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. Gynecol Oncol 1997; 67: 277-84.
14. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP,. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-73.
15. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
16. Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM,. The molecular pathogenesis of hereditary ovarian carcinoma. Cancer 2010; 116: 5261-71.
17. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD,. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49-56.
18. Velicescu M, Yu J, Herbert BS, Shay JW, Granada E, Dubeau L,. Aneuploidy and telomere attrition are independent determinants of crisis in SV40-transformed epithelial cells. Cancer Res 2003; 63: 5813-20.
19. Schonthal AH,. Measuring cyclin-dependent kinase activity. Methods Mol Biol 2004; 281: 105-24.
20. Hsieh CL,. Basic cytogenetic techniques: culture, slidemaking and bandinged, 2nd edn. New York: Academic Press, 1997.
21. Hoyt MA, Totis L, Roberts BT,. S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell 1991; 66: 507-17.
22. Li R, Murray AW,. Feedback control of mitosis in budding yeast. Cell 1991; 66: 519-31.
23. Taylor SS, Ha E, McKeon F,. The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. J Cell Biol 1998; 142: 1-11.
24. Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, Ruderman JV, Hershko A,. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995; 6: 185-97.
25. Hagting A, Den Elzen N, Vodermaier HC, Waizenegger IC, Peters JM, Pines J,. Human securin proteolysis is controlled by the spindle checkpoint and reveals when the APC/C switches from activation by Cdc20 to Cdh1. J Cell Biol 2002; 157: 1125-37.
26. Thornton BR, Toczyski DP,. Securin and B-cyclin/CDK are the only essential targets of the APC. Nat Cell Biol 2003; 5: 1090-4.
27. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH,. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 1996; 56: 3168-72.
28. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD,. Cell cycle control of BRCA2. Cancer Res 1996; 56: 4590-4.
29. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM,. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88: 265-75.
30. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM,. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999; 4: 1093-9.
31. Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F, Shiekhattar R,. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000; 102: 257-65.
32. Wu W, Sato K, Koike A, Nishikawa H, Koizumi H, Venkitaraman AR, Ohta T,. HERC2 is an E3 ligase that targets BRCA1 for degradation. Cancer Res 2010; 70: 6384-92.
33. Xu B, Kim ST, Kastan MB,. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing radiation. Mol Cell Biol 2001; 21: 3445-50.
34. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC,. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002; 30: 285-9.
35. Cornelis RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BA, Tonin P, Hamann U, Lindblom A, Lalle P,. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 1995; 13: 203-10.
36. Neuhausen SL, Marshall CJ,. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res 1994; 54: 6069-72.
37. Smith SA, Easton DF, Evans DG, Ponder BA,. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992; 2: 128-31.
38. Rice JC, Massey-Brown KS, Futscher BW,. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998; 17: 1807-12.
39. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW, Minna JD, Gazdar AF,. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998; 58: 3237-42.
40. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F,. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996; 85: 1009-23.
41. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T,. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68: 2581-6.
42. Chodankar R, Kwang S, Sangiorgi F, Hong H, Yen HY, Deng C, Pike MC, Shuler CF, Maxson R, Dubeau L,. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 2005; 15: 561-5.
43. Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R, Dubeau L,. Changes in the mouse estrus cycle in response to Brca1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res 2010; 70: 221-8.
44. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H,. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005; 7: R93-R100.
45. Turner NC, Reis-Filho JS,. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-53.